Efficacy

No RCTs were found. A phase II open trial compared two doses (6-5 mg/m2/day and 650 mg/m2/day) of oral bexarotene in 58 patients with refractory stage IA-IIA CTCL.62 The optimal dose was 300 mg/m2/day in terms of response and tolerability. Objective responses of 20%, 54% and 67% were noted at the 6-5, 300 and 650 mg/m2/day doses, respectively. Rates of disease progression were 47%, 21% and 13%, respectively. Median duration of response at the highest dose level was 516 days. In late stages of disease (stage IIB-IVB) OR rates of 45% (at 300 mg/m2/day) and 55% (at doses >300 mg/m2/day) have been reported with a relapse rate of 36% and projected median duration of response of 299 days.63

0 0

Post a comment